AAPL   316.73 (-0.68%)
MSFT   181.57 (-1.06%)
FB   232.20 (-1.15%)
GOOGL   1,421.37 (+0.58%)
AMZN   2,421.86 (-0.62%)
NVDA   348.71 (-3.42%)
CGC   20.01 (+3.04%)
BABA   201.72 (+1.01%)
MU   45.80 (+1.91%)
GE   6.80 (+6.08%)
TSLA   818.87 (+0.24%)
AMD   53.19 (-3.59%)
T   30.82 (+3.15%)
ACB   15.61 (-2.50%)
F   5.84 (+3.36%)
GILD   73.18 (-0.22%)
DIS   120.95 (+2.48%)
NFLX   414.77 (-3.39%)
BAC   24.28 (+7.15%)
BA   144.73 (+5.24%)
AAPL   316.73 (-0.68%)
MSFT   181.57 (-1.06%)
FB   232.20 (-1.15%)
GOOGL   1,421.37 (+0.58%)
AMZN   2,421.86 (-0.62%)
NVDA   348.71 (-3.42%)
CGC   20.01 (+3.04%)
BABA   201.72 (+1.01%)
MU   45.80 (+1.91%)
GE   6.80 (+6.08%)
TSLA   818.87 (+0.24%)
AMD   53.19 (-3.59%)
T   30.82 (+3.15%)
ACB   15.61 (-2.50%)
F   5.84 (+3.36%)
GILD   73.18 (-0.22%)
DIS   120.95 (+2.48%)
NFLX   414.77 (-3.39%)
BAC   24.28 (+7.15%)
BA   144.73 (+5.24%)
AAPL   316.73 (-0.68%)
MSFT   181.57 (-1.06%)
FB   232.20 (-1.15%)
GOOGL   1,421.37 (+0.58%)
AMZN   2,421.86 (-0.62%)
NVDA   348.71 (-3.42%)
CGC   20.01 (+3.04%)
BABA   201.72 (+1.01%)
MU   45.80 (+1.91%)
GE   6.80 (+6.08%)
TSLA   818.87 (+0.24%)
AMD   53.19 (-3.59%)
T   30.82 (+3.15%)
ACB   15.61 (-2.50%)
F   5.84 (+3.36%)
GILD   73.18 (-0.22%)
DIS   120.95 (+2.48%)
NFLX   414.77 (-3.39%)
BAC   24.28 (+7.15%)
BA   144.73 (+5.24%)
AAPL   316.73 (-0.68%)
MSFT   181.57 (-1.06%)
FB   232.20 (-1.15%)
GOOGL   1,421.37 (+0.58%)
AMZN   2,421.86 (-0.62%)
NVDA   348.71 (-3.42%)
CGC   20.01 (+3.04%)
BABA   201.72 (+1.01%)
MU   45.80 (+1.91%)
GE   6.80 (+6.08%)
TSLA   818.87 (+0.24%)
AMD   53.19 (-3.59%)
T   30.82 (+3.15%)
ACB   15.61 (-2.50%)
F   5.84 (+3.36%)
GILD   73.18 (-0.22%)
DIS   120.95 (+2.48%)
NFLX   414.77 (-3.39%)
BAC   24.28 (+7.15%)
BA   144.73 (+5.24%)
Log in

NASDAQ:ENDPEndo International Stock Price, Forecast & News

$3.83
-0.03 (-0.78 %)
(As of 05/26/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.79
Now: $3.83
$4.03
50-Day Range
$3.18
MA: $3.95
$4.68
52-Week Range
$1.97
Now: $3.83
$7.10
Volume4.77 million shs
Average Volume6.15 million shs
Market Capitalization$879.77 million
P/E RatioN/A
Dividend YieldN/A
Beta1.61
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals. The U.S. Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, sprays, and sterile injectables, as well as products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The U.S. Branded Pharmaceuticals segment provides XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's diseases; SUPPRELIN LA for central precocious puberty treatment; TESTOPEL, a long-acting implantable pellet for the treatment of central precocious puberty; NASCOBAL, a nasal spray to treat vitamin B12 deficiency; and AVEED for the treatment of hypogonadism. This segment also offers pain management products, such as PERCOCET, VOLTAREN Gel, and LIDODERM; TESTIM Gel for the treatment of endogenous testosterone; and FORTESTA Gel for hypogonadism treatment. The International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, and oncology. It sells its branded pharmaceuticals and generics directly to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.
Read More
Endo International logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.47 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:ENDP
CUSIP29264F20
Phone011-353-1268-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.91 billion
Cash Flow$5.18 per share
Book Value($3.82) per share

Profitability

Net Income$-422,640,000.00

Miscellaneous

Employees3,172
Market Cap$879.77 million
Next Earnings Date8/3/2020 (Estimated)
OptionableOptionable

Receive ENDP News and Ratings via Email

Sign-up to receive the latest news and ratings for ENDP and its competitors with MarketBeat's FREE daily newsletter.

Endo International (NASDAQ:ENDP) Frequently Asked Questions

How has Endo International's stock been impacted by COVID-19 (Coronavirus)?

Endo International's stock was trading at $3.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ENDP stock has decreased by 1.5% and is now trading at $3.83. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Endo International?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endo International in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Endo International.

When is Endo International's next earnings date?

Endo International is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Endo International.

How were Endo International's earnings last quarter?

Endo International PLC (NASDAQ:ENDP) announced its quarterly earnings data on Thursday, May, 7th. The company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.55 by $0.40. The firm had revenue of $820.40 million for the quarter, compared to analysts' expectations of $713.62 million. Endo International had a negative net margin of 9.09% and a negative return on equity of 91.00%. Endo International's revenue for the quarter was up 13.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.60 earnings per share. View Endo International's earnings history.

What guidance has Endo International issued on next quarter's earnings?

Endo International issued an update on its FY20 earnings guidance on Wednesday, February, 26th. The company provided EPS guidance of $2.15-2.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.25. The company issued revenue guidance of $2.72-2.92 billion, compared to the consensus revenue estimate of $2.90 billion.

What price target have analysts set for ENDP?

8 equities research analysts have issued 12-month target prices for Endo International's stock. Their forecasts range from $3.00 to $7.00. On average, they anticipate Endo International's stock price to reach $5.72 in the next year. This suggests a possible upside of 49.3% from the stock's current price. View analysts' price targets for Endo International.

Has Endo International been receiving favorable news coverage?

Media headlines about ENDP stock have been trending somewhat negative on Tuesday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Endo International earned a coverage optimism score of -1.9 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutEndo International.

Are investors shorting Endo International?

Endo International saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 26,100,000 shares, a decrease of 11.6% from the April 30th total of 29,540,000 shares. Based on an average trading volume of 6,200,000 shares, the days-to-cover ratio is currently 4.2 days. Approximately 13.6% of the shares of the company are sold short. View Endo International's Current Options Chain.

Who are some of Endo International's key competitors?

What other stocks do shareholders of Endo International own?

Who are Endo International's key executives?

Endo International's management team includes the following people:
  • Mr. Paul V. Campanelli, Pres, CEO & Director (Age 57)
  • Mr. Blaise Coleman, Exec. VP & CFO (Age 45)
  • Mr. Terrance J. Coughlin, Exec. VP & COO (Age 53)
  • Mr. Matthew Joseph Maletta, Exec. VP & Chief Legal Officer (Age 47)
  • Mr. Antonio R. Pera, Pres of Par Pharmaceutical (Age 62)

What is Endo International's stock symbol?

Endo International trades on the NASDAQ under the ticker symbol "ENDP."

Who are Endo International's major shareholders?

Endo International's stock is owned by many different institutional and retail investors. Top institutional investors include Geode Capital Management LLC (1.44%), Bank of New York Mellon Corp (1.00%), Rhumbline Advisers (0.28%), Parametric Portfolio Associates LLC (0.20%), New York State Teachers Retirement System (0.14%) and Globeflex Capital L P (0.12%). Company insiders that own Endo International stock include Nancy J Hutson, Roger H Kimmel and William P Montague. View institutional ownership trends for Endo International.

Which institutional investors are selling Endo International stock?

ENDP stock was sold by a variety of institutional investors in the last quarter, including Arizona State Retirement System, Bank of New York Mellon Corp, Systematic Financial Management LP, Parametric Portfolio Associates LLC, Globeflex Capital L P, Dupont Capital Management Corp, American International Group Inc., and New York State Teachers Retirement System. View insider buying and selling activity for Endo International.

Which institutional investors are buying Endo International stock?

ENDP stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Acadian Asset Management LLC, Russell Investments Group Ltd., Rhumbline Advisers, BNP Paribas Arbitrage SA, Teza Capital Management LLC, Hunter Associates Investment Management LLC, and Nisa Investment Advisors LLC. View insider buying and selling activity for Endo International.

How do I buy shares of Endo International?

Shares of ENDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Endo International's stock price today?

One share of ENDP stock can currently be purchased for approximately $3.83.

How big of a company is Endo International?

Endo International has a market capitalization of $879.77 million and generates $2.91 billion in revenue each year. The company earns $-422,640,000.00 in net income (profit) each year or $2.38 on an earnings per share basis. Endo International employs 3,172 workers across the globe.

What is Endo International's official website?

The official website for Endo International is www.endo.com.

How can I contact Endo International?

Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company can be reached via phone at 011-353-1268-2000 or via email at [email protected]

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.